Page 1of 38
___________________________________________________________________________
Title:
Clinical Comparison of [ADDRESS_767147] Lenses
Protocol Number:
Sponsor Name [CONTACT_13311]:
Test Product(s):
Investigator Agreement:CLE383-C 004 / [STUDY_ID_REMOVED]
Alcon Research, Ltd.
[ADDRESS_767148] Lenses (DD T2 Contact 
[CONTACT_32993])
I have read the clinical study described herein, recognize its 
confidentiality , and agree to conduct the described trial in 
compliance with Good Clinical Practice (GCP), the ethical 
principles contained within the Declaration of Helsinki, this 
protocol, and all applicable
 regulatory requirements.  
Additionally , I will
 comply with all procedures for data 
recording and reporting, will permit monitoring, auditing, and 
inspection of my
 research center, and will retain all records until 
notified by [CONTACT_1034].
Principal I nvestigator:
Signature [CONTACT_13312]:
Address:
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767149] D D T 2 
Na me of C o ntr ol 
Pr o d ucts A C U V U E O A S Y S ®Bra n d C o ntact Le nses 1- D a y  wit h 
H y dra L u xe ™ Tec h n ol o g y  ( Oas y s 1- D a y )
C o o per Visi o n ®M y D a y ®( M y D a y )
1- D a y  A C U V U E ®M OI S T ( M oist) 
Title of Trial Cli nical C o m paris o n of [ADDRESS_767150] Le nses 
Pr ot oc ol N u m ber C L E 3 8 3 -C 0 0 4 
N u m ber of Sites 
C o u ntr y ~ 3 
U S 
Pla n ne d D urati o n of 
E x p os ure ~ 2 0 da y s t otal d urati o n 
•Test Pr o d uct: 8 da y s ( -1/ + 2 da y s) 
•C o ntr ol Pr o d uct s: 8 da y s ( -1/ + 2 da y s) 
N u m ber of S u bjects  Tar get t o c o m plete: 6 0 ( 2 0 per eac h parallel gr o u p) 
Pla n ne d t o e nr oll: ~ 6 6 ( ~ 2 2 per eac h parallel gr o u p) 
St u d y  P o p ulati o n V ol u nteer s u bjects a ge d [ADDRESS_767151] le ns wearers (e xcl u di n g c urre nt Oas ys  1- D a y , M y D a y ,a n d 
M oist wearers), ha ve at least [ADDRESS_767152] le nses .
E n d p oi nts Pri mar y  Effecti ve ness 
O verall q ualit y of visi o n Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 5 0 6 P r o t o c o l  -  C l i n i c a l 0 2- N o v- 2 0 1 7 
Pa ge 3of 3 8 
Safet y 
A Es 
Bi o micr osc o p y fi n di n gs 
De vice deficie ncies 
Assess me nts Effecti ve ness 
-V A ( S nelle n dista nce) 
-O verall q ualit y of visi o n 
Safet y 
-A Es 
-Bi o micr osc o p y
-De vice deficie ncies 
St u d y  Desi g n Pr os pecti ve Si n gle -mas ke d 
(trial s u bject) 
Si n gle -mas ke d (I n vesti gat or) 
D o u ble- mas ke d 
O pe n -la be l
Ot her Si n gle gr o u p 
Parallel gr o u p 
Cr oss o ver 
Ot her 
C o ntralateral 
Bilateral 
M o n oc ular le ns wear Ra n d o mize d 
T his is a [ADDRESS_767153] u d y  L e ns 2 bilaterall y  f or a p pr o xi matel y  1 wee k.  T his 
sa me desi g n will be sc he d ule d f or eac h of t he 3 ar ms. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 5 0 6 P r o t o c o l  -  C l i n i c a l 0 2- N o v- 2 0 1 7 
Page 4of 38
Study  Visits:  
1.Baseline/Dispense Lens 1
2. D ay 8 (-1/+2 day s) follow - up Lens 1/Dispense Lens 2
3. D ay 8 (-1/+2 day s) follow - up Lens 2/Exit
Test Product Details Primary  component/material
Product Name [INVESTIGATOR_1652] T2
LID Number LID 006841
Manufacturer Alcon
Other The lenses will be available in 
-1.00 D to - 6.00 D (0.25 D steps)
Control Product 1 
DetailsPrimary  component/material senofilcon A
Product Name [CONTACT_583631] 1-Day
LID Number LID 009601
Manufacturer Johnson and Johnson Vision
Other The lenses will be available in 
-1.00 D to - 6.00 D (0.25D steps)
Control Product 2
DetailsPrimary  component/material stenfilcon A
Product Name [CONTACT_583632] 009602
Manufacturer CooperVision
Other The lenses will be available in 
-1.00 D to - 6.00 D (0.25 D steps)
Control Product 3
DetailsPrimary  component/material etafilcon A
Product Name [CONTACT_583633] 009603
Manufacturer Johnson and Johnson Vision
Other The lenses will be available in 
-1.00 D to - 6.00 D (0.25 D steps)
Inclusion Criteria 1.Subject must be at least [ADDRESS_767154] cy linder ≤ 0.75 D in each ey e.
5.BCVA 20/[ADDRESS_767155] 
lenses for the duration of study  participation.  
Exclusion Criteria 1.Any anterior segment infection, inflammation, or abnormality  or 
disease ( including s ystemic) that contraindicates contact [CONTACT_13279], 
as determined b y the Investigator.
2.Any use of s ystemic or ocular medications for which contact [CONTACT_583624], as determined b y the Investigator.
3.History  of refractive surgery  or plan to have refractive surgery  
during the stud y or irregular cornea in either ey e.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054506
Protocol - Clinical
02-Nov-2017

Pa ge 5of 3 8 
4. Oc ular or i ntra oc ular s ur ger y  (e xcl u di n g place me nt of p u nctal 
pl u gs) wit hi n t he pre vi o us [ADDRESS_767156] u d y. 
5. Bi o micr osc o p y fi n di n gs at scree ni n g t hat are m o derate ( Gra de 3) or 
hi g her a n d/ or c or neal vasc ularizati o n t hat is mil d ( Gra de 2) or 
hi g her. 
6. C urre nt or hist or y  of pat h ol o gicall y dr y e y e i n eit her e y e t hat, i n t he 
o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or, w o ul d precl u de c o ntact le ns wear. 
7. C urre nt or hist or y  of h er petic keratitis i n eit her e ye. 
8. E y e i nj ur y  i n eit her e y e wit hi n [ADDRESS_767157] le nses i n a n e xte n de d wear m o dalit y  
(r o uti nel y  slee pi n g i n le nses f or at least 1 ni g ht per wee k) o ver t he 
last [ADDRESS_767158] le ns 
wear. 
1 2. T he I n vesti gat or, his/ her staff, fa mil y me m bers of t he I n vesti gat or, 
fa mil y  me m bers of t he I n vesti gat or’s staff, or i n di vi d uals li vi n g i n 
t he h o use h ol ds of t he af ore me nti o ne d pers o ns ma y n ot partici pate 
i n t he st u d y . 
[ADDRESS_767159] 
3 m o nt hs. 
Ass ociate d Materials L u bricati o n/re -wetti n g dr o ps will n ot be per mitte d. 
Ta ble 1–[ADDRESS_767160] u d y Pr oce d ur es a n d Assess me nts 
Pr oce d ure/ Assess me nt Visit 1, D a y 1: 
Baseli ne/ 
Dis pe nse 
Le ns 1Visit 2, Wee k 1: 
D a y  8 of le ns 
wear 
(- 1/ + 2 da ys) 
F oll o w - u p Le ns 1/ 
Dis pe nse Le ns 2Visit 3, Wee k 2: 
D a y  8 of le ns 
wear 
(- 1/ + 2 da ys) 
F oll o w - u p Le ns 2/ 
E xit U nsc he d ule d 
Visit 
I n f or me d C o nse nt  - - -
De m o gra p hics  - - -
Me dical Hist or y  - - -
C o nc o mita nt Me dicati o ns  () () ()
I n cl usi o n/ 
E xcl usi o n  - - -
Ha bit ual le ns 
( bra n d, p o wer) * - - -Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 5 0 6 P r o t o c o l  -  C l i n i c a l 0 2- N o v- 2 0 1 7 
Pa ge 6of 3 8 
Pr oce d ure/ Assess me nt Visit 1, D a y 1: 
Baseli ne/ 
Dis pe nse 
Le ns 1Visit 2, Wee k 1: 
D a y  8 of le ns 
wear 
(- 1/ + 2 da ys) 
F oll o w - u p Le ns 1/ 
Dis pe nse Le ns 2Visit 3, Wee k 2: 
D a y  8 of le ns 
wear 
(- 1/ + 2 da ys) 
F oll o w - u p Le ns 2/ 
E xit U nsc he d ule d 
Visit 
V A w/ ha bit ual c orrecti o n 
(O D, O S, S nelle n 
dista nce) * -  ()
Bi o micr osc o p y    
Dis pe nse st u d y  le nses   - -
V A w/ st u d y le nses (O D, 
O S, S nelle n dista nce )   ()
S u bjecti ve rati n g wit h 
st u d y  le nses: 
•
•  
•
•
•o verall q ualit y of visi o n 
•
•-
( F oll o w - u p 
Le ns 1)  Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 5 0 6 P r o t o c o l  -  C l i n i c a l 0 2- N o v- 2 0 1 7 
Pa ge 7of 3 8 
Pr oce d ure/ Assess me nt Visit 1, D a y 1: 
Baseli ne/ 
Dis pe nse 
Le ns 1Visit 2, Wee k 1: 
D a y  8 of le ns 
wear 
(- 1/ + 2 da ys) 
F oll o w - u p Le ns 1/ 
Dis pe nse Le ns 2Visit 3, Wee k 2: 
D a y  8 of le ns 
wear 
(- 1/ + 2 da ys) 
F oll o w - u p Le ns 2/ 
E xit U nsc he d ule d 
Visit 
A E s    
De vice deficie ncies    
E xit F or m () () () ()
() assess me nt perf or me d as necessar y , e g, decrease of V A b y [ADDRESS_767161] (I P) 
* S o urce o nl y 
ᵼC o m me nts, o pti o nal 
1. 1 A b bre vi ati o ns 
Ta ble 1 – [ADDRESS_767162] u g A d mi nistrati o n 
G C P G o o d Cli nical Practice 
I B I n vesti gat or ’s  br oc h ure 
I C F I n f or me d c o nse nt f or m 
I P I n vesti gati o nal pr o d uct 
I R B I nstit uti o nal re vie w b oar d 
I S O I nter nati o nal Or ga nizati o n f or Sta n dar dizati o n 
m m Milli meter 
M O P Ma n ual of pr oce d ures 
N/ A N ot a p plica ble 
O D Ri g ht e y e
O S Left e y e
O U B ot h e y es 
S A E Seri o us a d verse e ve nt 
S A D E Seri o us a d verse de vice effect 
U S U nite d States 
U S A D E U na ntici pate d seri o us a d verse de vice ef fect 
V A Vi s ual ac uit y Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767163] Population .............................................................................................12
3.5 Outline of Study ................................................................................................12
4TREA TMENTS ADMINISTERED ...................................................................................12
4.1 Identity  of Study  Treatments .............................................................................13
4.2 Accountability  Procedures .................................................................................14
5STUDY  PROCEDURES AND ASSESSMENTS .............................................................15
5.1 Visits and Examinations ....................................................................................15
5.1.1 Visit 1 (Day  1) –Baseline/Dispense Lens 1 ......................................15
5.1.2 Visit 2, Week 1 [Day  8 (
-1/+2 Day s)] –Follow -Up L ens 1/Dispense 
Lens 2 ................................................................................................17
5.1.3 Visit 3, Week 2 [Day  8 (
-1/+2 Day s)] –Follow -Up L ens 2/Exit .......[ADDRESS_767164] Evaluability ................................ ................................ ...........................23
6.2 Analy sis Data Sets ................................ ................................ .............................23
6.2.1 Safety  Analysis Set ................................ ................................ ............23
6.3 Demographic and Baseline Characteristics................................ .......................23
6.4 Effectiveness Anal yses................................ ................................ ......................23
6.4.1 Primary  Effectiveness ................................ ................................ ........23
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054506
Protocol - Clinical
02-Nov-2017
Page 9of 38
[IP_ADDRESS] Statistical Hy potheses ........................................................23
[IP_ADDRESS] Analy sis Methods ..............................................................[ADDRESS_767165] (IRB) ................................ ................................ .....[ADDRESS_767166] ORY................................ ................................ ..........38
12REFERENCES ................................ ................................ ................................ ..................38
12.1 References applicable for all clinical trials ................................ .......................38
12.1.1 US references applicable for clinical trials ................................ ........38
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767167] of Tables
Table1–1 Schedule of Study  Procedures and Assessments ................................ ...............5
Table1–2 Table of Abbreviations .......................................................................................7
Table4–[ADDRESS_767168] of Figur es
Figure 7–1 Categorization of All AEs................................ ................................ ................28
Figure 7-2 Categorization of All Serious Adverse Events ................................ .................29
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767169] performance in the intended population. The 
primary  endpoint w asselected to fulfil the primary  objective of the study . Procedures for 
measurement of these endpoints were selected based on common practice for these 
assessments. The design of this study is justified based upo n preclinical and clinical testing, 
as described within the Investigator ’s Brochure. Oasys 1-Day, MyDay,and Moist contact 
[CONTACT_583625] .
The new contact [CONTACT_583626] i ntended for the optical correction of refractive 
myopia in persons with non -diseased ey es.
There are no immediate plans to submit the results of this study  for publication; however, the 
results may  be offered for publication if they  are of scientific inte rest, or if the results relate 
to a product that is subsequently  approved or cleared for marketing.
3.[ADDRESS_767170] lens wear .
Based upon non -clinical testing and/or documented rationale for applicability  of test results 
to the I P, the new contact [CONTACT_66220] -toxic and biocompatible 
for on -eye use. 
The new contact [CONTACT_583627] [ADDRESS_767171] lense s arenot intended for use 
with a cleaning/disinfecting solution, and the biocompatibility with lens care solutions and 
any associated clinical effects are unknown.
A summary  of the known potential risks and benefits associated with the new contact [CONTACT_66222] I nvestigator ’s Brochure. There may  also be unknown risks 
with the use of the 
new contact [CONTACT_13293]. Risks are minimized by  [CONTACT_583628], and through clos e supervision by  a licensed clinician during 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767172] of subjects with normal ey es (other than the n
eed for optical correction for 
myopia), and who are adapted, existing wearers of daily  disposable soft contact [CONTACT_583629].
Subjects must be screened according to the full list of inclusion/exclusion criteria in Section [ADDRESS_767173] lens will be 
evaluated compared to 1of 3chosen control lenses.  Subjects will be randomized to 1 of the 
6 lens sequences, as described below:
Sequence 1: DD T2 → Oasy s 1-Day 
Sequence 2: Oasy s 1-Day →DD T2 
Sequence 3: DD T2 → MyDay 
Sequence 4: My Day →DD T2 
Sequence 5: DD T2 → Moist 
Sequence 6: Moist →DD T2
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767174] u d y Tr e at me nts 
Ta ble 4 – [ADDRESS_767175] 
Material se n o filc o n A ste nfilc o n A etafilc o n A
Wa ter C o nte nt 3 8 % 5 4 % 5 8 % 
Base C ur ve 
( m m) 8. 3 8. 5 8. 4 8. 5 
Dia meter 
( m m) [ADDRESS_767176] u d y -1. 0 0 t o - 6. 0 0 D 
( 0. 2 5 D ste ps) - 1. 0 0 t o - 6. 0 0 D 
( 0. 2 5 ste ps) -1. 0 0 t o - 6. 0 0 D 
( 0. 2 5 D ste ps) -1. 0 0 t o - 6. 0 0 D 
( 0. 2 5 D ste ps) 
Pac ka gi n g, 
La beli n g, a n d 
S u p pl y Blister f oil 
pac k 
F oil la bel 
i ncl u des at a 
mi ni m u m: 
-material 
na me a n d/ or 
i de ntifier 
-base c ur ve 
-dia meter 
-ma n ufact uri n 
g pr ot oc ol 
n u m ber 
-pac ki n g 
s ol uti o n 
-p o wer 
-l ot n u m ber 
- e x pi[INVESTIGATOR_1313] o n 
date 
-c o nte nt 
state me nt 
-i n vesti gati o na 
l de vice 
state me nt 
-S p o ns or 
i nf or mati o n 
-c o u ntr y of 
ori gi n 
Pr o vi de d i n 
b o xes of 1 2 
le nses per Blister f oil 
pac k 
F oil la bel 
i ncl u des at a 
mi ni m u m: 
-material 
na me 
a n d/ or 
i de ntifier 
-base c ur ve 
-dia meter 
-pac ki n g 
s ol uti o n 
-p o wer 
-l ot n u m ber 
- e x pi[INVESTIGATOR_1313] o n 
date 
-c o nte nt 
state me nt 
-i n vesti gati o 
nal de vice 
state me nt 
-S p o ns or 
i nf or mati o n 
-c o u ntr y of 
ori gi n 
Pr o vi de d i n 
b o xes of 1 2 
le nses per 
p o wer per 
b o x,  Blister f oil 
pac k 
F oil la bel 
i ncl u des at a 
mi ni m u m: 
-material 
na me a n d/ or 
i de ntifier 
-base c ur ve 
-dia meter 
-pac ki n g 
s ol uti o n 
-p o wer 
-l ot n u m ber 
- e x pi[INVESTIGATOR_1313] o n 
date 
-c o nte nt 
state me nt 
-i n vesti gati o 
nal de vice 
state me nt 
-S p o ns or 
i nf or mati o n 
-c o u ntr y of 
ori gi n 
Pr o vi de d i n 
b o xes of 1 2 
le nses per 
p o wer per 
b o x,  
i de ntifie d wit h Blister f oil 
pac k 
F oil la bel 
i ncl u des at a 
mi ni m u m: 
-material 
na me a n d/ or 
i de ntifier 
-base c ur ve 
-dia meter 
-pac ki n g 
s ol uti o n 
-p o wer 
-l ot n u m ber 
- e x pi[INVESTIGATOR_1313] o n 
date 
-c o nte nt 
state me nt 
-i n vesti gati o 
nal de vice 
state me nt 
-S p o ns or 
i nf o r mati o n 
-c o u ntr y of 
ori gi n 
Pr o vi de d i n 
b o xes of 1 2 
le nses per 
p o wer per 
b o x,  
i de ntifie d wit h Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 5 0 6 P r o t o c o l  -  C l i n i c a l 0 2- N o v- 2 0 1 7 
Pa ge 1 4 of 3 8 
p o wer per b o x, 
i de ntifie d wit h 
t he f oll o wi n g 
at a mi ni m u m: 
-a c ol or c o de d 
la bel stati n g 
t he pr ot oc ol 
n u m ber 
-material 
i de ntifier 
-p o wer 
-a n 
i n vesti gati o na 
l use o nl y 
state me nt 
-trac ki n g 
n u m ber 
Le nses s h o ul d 
be st ore d at 
r o o m 
te m perat ure. i de ntifie d 
wit h t he 
f oll o wi n g at a 
mi ni m u m: 
-a c ol or 
c o de d la bel 
stati n g t he 
pr ot oc ol 
n u m ber 
-material 
na me or 
i de ntifier 
-p o wer 
-a n 
i n vesti gati o 
nal use o nl y 
state me nt 
-trac ki n g 
n u m ber 
Le nses s h o ul d 
be st ore d at 
r o o m 
te m perat ure. t he f oll o wi n g 
at a mi ni m u m: 
-a c ol or 
c o de d la bel 
stati n g t he 
pr ot oc ol 
n u m ber 
-material 
na me or 
i de ntifier 
-p o wer 
-a n 
i n vesti gati o 
nal use o nl y 
state me nt 
-trac ki n g 
n u m ber 
Le nses s h o ul d 
be st ore d at 
r o o m 
te m perat ure. t he f oll o wi n g 
at a mi ni m u m: 
-a c ol or 
c o de d la bel 
stati n g t he 
pr ot oc ol 
n u m ber 
-material 
na me or 
i de ntifier 
-p o wer 
-a n 
i n vesti gati o 
nal use o nl y 
state me nt 
-trac ki n g 
n u m ber 
Le nses s h o ul d 
be st ore d at 
r o o m 
te m perat ure. 
Usa ge Wear: 
oDail y  w ear 
oBilateral, parallel cr oss o ver gr o u p 
Re place me nt peri o d: Dail y  Dis p osa ble 
E x p os ure: At least [ADDRESS_767177] u d y  treat me nt d urati o n. 
Le ns Care: N/ A 
4. [ADDRESS_767178] u d y  m o nit or f or t he p ur p oses of verif y i n g t he acc o u nti n g of cli nical 
s u p plies. A n y discre pa ncies a n d/ or deficie ncies bet wee n t he o bser ve d dis p ositi o n a n d t he 
writte n acc o u nt m ust be rec or de d al o n g wit h a n e x pla nati o n. 
It is t he I n vesti gat or ’s  res p o nsi bilit y  t o e ns ure t hat: 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767179] u d y  pr o d ucts are acc o u nte d f or a n d n ot use d i n a n y  u na ut h orize d ma n ner 
Pa ge 1 5 of 3 8 
All use d f oils a n d u n use d s u p plies are ret ur ne d b y eac h s u bject 
All u n use d pr o d ucts are a vaila ble f or ret ur n t o t he St u d y  S p o ns or , as directe d 
A n y  st u d y  le nses ass ociate d wit h a de vice deficie nc y  or wit h a n y  pr o d uct -relate d 
a d verse e ve nt [ie, A D E or S A D E] are ret ur ne d t o t he St u d y  S p o ns or f or i n vesti gati o n. 
Refer t o Secti o n 7. [ADDRESS_767180] u d y  pr o d ucts ass ociate d wit h t hese 
e ve nts. 
5S T U D Y  P R O C E D U R E S A N D A S S E S S M E N T S 
5. 1 Vi sits a n d E x a mi n ati o ns 
5. 1. 1 Vi sit 1 ( D a y 1) –B aseli ne/ Dis pe nse Le ns [ADDRESS_767181]’s c hart. After si g ni n g 
t he I C F , a s u bject will be assi g ne d a s u bject n u m ber b y t he E D C s y ste m . A si g ne d 
i nf or me d c o nse nt d oc u me nt defi nes t he p oi nt of e nr oll me nt. 
[ADDRESS_767182] 3 0 da y s. I ncl u de her bal t hera pi[INVESTIGATOR_014], vita mi ns, a n d all 
over -t he -c o u nter as well as prescri pti o n me dicati o ns. 
3
4 Perf or m S nelle n V A wit h ha bit ual c orrecti o n. 
 O D , O S, dista nce o nl y,  c o ntact le nses 
 O ver -refracti o n ( o nl y nee de d if V A is re d uce d) 
Rec or d ha bit ual le ns i nf or mati o n ( bra n d, p o wer). 
5
6Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 5 0 6 P r o t o c o l  -  C l i n i c a l 0 2- N o v- 2 0 1 7 
Pa ge 1 6 of 3 8 
7 Perf or m slit -la m p bi o micr osc o p y ( wit h o ut c o ntact le nses) t o e val uate t he f oll o wi n g: 
Li m bal h y pere mia 
B ul bar h y p ere mia 
C or neal stai ni n g 
C o nj u ncti val stai ni n g 
Pal pe bral c o nj u ncti val o bser vati o ns 
C or neal e pit helial e de ma 
C or neal str o mal e de ma 
C or neal vasc ularizati o n 
C o nj u ncti val c o m pressi o n/i n de nti o n 
C he m osis 
C or neal i nfiltrates 
Ot her fi n di n gs 
8  
9 Re vie w i ncl usi o n/ e xcl usi o n criteria t o deter mi ne if t he s u bject q ualifies t o be 
ra n d o mize d i nt o t he st u d y . I f s u bject q ualifies, re q uest ra n d o mizati o n. I f s u bject d oes 
n ot q ualif y , e xit t he s u bject fr o m t he st u d y as a scree n fail ure. 
[ADDRESS_767183] u d y  le nses .
Kee p all li d di n g f oils of le nses use d d uri n g le ns fit pr ocess f or st u dy le ns 
acc o u nt a bility. 
F oll o w pr oce d ures t o m ai nt ai n m aski n g. 
[ADDRESS_767184] u d y le nses b y  perf or mi n g t he f oll o wi n g: 
S nelle n V A wit h st u d y  le nses ( O D a n d O S, at dista nce) * 
O ver -refracti o n if necessar y  t o deter mi ne t he best c o ntact le ns- c orrecte d V A 
a n d fi nal st u d y  le ns p o wer(s) 
*V A w/st u dy le nses m ust be 2 0/ [ADDRESS_767185] t o le av e t he office Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767186] u d y  visit. 
N ote: A Es a n d device deficie ncies m ust be rec or de d f or all e nr olle d s u bjects fr o m t he ti me of 
si g n at ure of i nf or me d c o nse nt i ncl u di n g t h ose t h at scree n f ail. 
[ADDRESS_767187] u d y  le nses ( Le ns 1) . Pr o vi de t he s u bject wit h writte n a n d ver bal 
i nstr ucti o ns o n le ns wear .
[ADDRESS_767188] o n D a y  8 (- 1/ + 2 da y s) of le ns wear ( Le ns 1) .
1 7 N ote: If f or s o me re as o n a s u bject is u n a ble t o we ar a st u dy le ns f or t he d ur ati o n of t his visit 
wi n d o w , i nstr uct t he s u bject t o ret ur n t o t he site f or a n U nsc he d ule d Visit as well as le ns 
re m ov al o n site, if p ossi ble. T he s u bject s h o ul d t he n be sc he d ule d t o ret ur n t o t he cli nic f or 
Visit 2(if p ossi ble) or exite d fr o m t he st u dy. 
5. 1. 2 Vi sit 2, We e k  1 [D a y 8 (- 1/ + 2 D a ys) ] – F oll o w -U p Le ns 1/ Dis pe nse 
Le ns 2 
1 O btai n i nf or mati o n o n a n y  c ha n ges i n me dical healt h a n d/ or t he use of c o nc o mita nt 
me dicati o ns. 
2 Rec or d a n y de vice deficie ncies or A Es i ncl u di n g t h ose ass ociate d wit h c ha n ges i n 
c o nc o mita nt me di cati o n d os i n g ,w hic h are o bser ve d or re p orte d si nce t he pre vi o us 
visit (s) .
[ADDRESS_767189] usa ge . 
4 A d mi nister S u bjecti ve Q uesti o n naire t o assess: 




S u bjecti ve o verall q ualit y  of visi o n, O U 

Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767190] u d y le nses b y perf or mi n g t he f oll o wi n g: 
S nelle n V A wit h st u d y  le nses ( O D a n d O S, at dista nce) 
6
7 Perf or m slit -la m p bi o micr osc o p y ( wit h o ut c o ntact le nses) t o e val uate t he f oll o wi n g: 
Li m bal h y pere mia 
B ul bar h y p ere mia 
C or neal stai ni n g 
C o nj u ncti val stai ni n g 
Pal pe bral c o nj u ncti val o bser vati o ns 
C or neal e pit helial e de ma 
C or neal str o mal e de ma 
C or neal vasc ularizati o n 
C o nj u ncti val c o m pressi o n /i n de nti o n 
C he m osis 
C or neal i nfiltrates 
Ot her fi n di n gs 
[ADDRESS_767191] u d y  le nses t o be e val uate d .
N ote: Kee p all li d di n g f oils of le nses use d d uri n g le ns fit pr ocess f or st u dy le ns 
acc o u nt a bility. 
[ADDRESS_767192] u d y le nses b y perf or mi n g t he f oll o wi n g: 
S nelle n V A wit h st u d y  le nses ( O D a n d O S, at dista nce) * 
O ver -refracti o n if necessar y  t o deter mi ne t he best c o ntact le ns- c orrecte d V A 
a n d fi nal st u d y  le ns p o wer(s) 
*V A w/st u dy le nses m ust be 2 0/ [ADDRESS_767193] t he office Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767194] u d y  visit. 
N ote: A Es a n d device deficie ncies m ust be r ec or de d f or all e nr olle d s u bjects fr o m 
t he ti me of si g n at ur e of i nf or me d c o nse nt r e g ar dless of t heir e nr oll me nt st at us 
(s cr ee n f ail ur e or r a n d o mize d). 
13Dis pe nse st u d y  le nses ( Le ns 2) .Pr o vi de t he s u bject wit h writte n a n d ver bal 
i nstr ucti o ns o n le ns wear .
[ADDRESS_767195] D a y  8 (- 1/ + 2 da y s) of le ns wear ( Le ns 2). 
1 5 N ote: If f or s o me re as o n a s u bject is u n a ble t o we ar a st u dy le ns f or t he d ur ati o n of t his 
visit wi n d o w , i nstr uct t he s u bject t o ret ur n t o t he site f or a n U nsc he d ule d Visit as well as 
le ns re m ov al o n site, if p ossi ble. T he s u bject s h o ul d t he n be sc he d ule d t o ret ur n t o t he cli nic 
f or Visit 3(if p ossi ble) or exite d fr o m t he st u dy. 
5. 1. 3 Vi sit 3, We e k  2 [ D a y 8 (- 1/ + 2 D a ys) ] – F oll o w -U p Le ns 2/ E xit 
1 O btai n i nf or mati o n o n a n y  c ha n ges i n me dical healt h a n d/ or t he use of c o nc o mita nt 
me dicati o ns. 
2 Rec or d a n yde vice deficie ncies or A Es i ncl u di n g t h ose ass ociate d wit h c ha n ges i n 
c o nc o mita nt me di cati o n d osi n g ,w hic h are o bser ve d or re p orte d si nce t he pre vi o us 
visit (s) .
[ADDRESS_767196] usa ge. 
4  A d mi nister S u bjecti ve Q uesti o n naire t o assess: 




S u bjecti ve o verall q ualit y  of visi o n, O U 


Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767197] u d y le nses b y perf or mi n g t he f oll o wi n g: 
S nelle n V A wit h st u d y  le nses ( O D a n d O S, at dista nce) 
6
7 Perf or m slit -la m p bi o micr osc o p y ( wit h o ut c o ntact le nses) t o e val uate t he f oll o wi n g: 
Li m bal h y pere mia 
B ul bar h y p ere mia 
C or neal stai ni n g 
C o nj u ncti val stai ni n g 
Pal pe bral c o nj u ncti val o bser vati o ns 
C or neal e pit helial e de ma 
C or neal str o mal e de ma 
C or neal vasc ularizati o n 
C o nj u ncti val c o m pressi o n/i n de nti o n 
C he m osis 
C or neal i nfiltrates 
Ot her fi n di n gs 
[ADDRESS_767198] u d y  visit. 
N ote: A Es a n d de vice deficie ncies m ust be rec or de d f or all e nr olle d s u bjects fr o m 
t he ti me of si g nat ure of i nf or me d c o nse nt re gar dless of t heir e nr oll me nt stat us 
(scree n fail ure or ra n d o mize d). 
9 Perf or m S nelle n V A wit h ha bit ual c orrecti o n. 
O D, O S, dista nce o nl y, c o ntact le nses 
N ote: If t his V A wit h h a bit u al c orr ecti o n s h o ws a decr e ase of 2 li nes or m or e vers us 
Vi sit 1 b aseli ne V A wit h h a bit u al c orr ecti o n, t he n B C V A wit h M R is r e q uir e d t o 
c o nfir m a p ote nti al l os s i n V A f or A E r e p orti n g r e q uir e me nts (see Secti o n 7). 
[ADDRESS_767199] u d y .Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767200] 
re q uires a n U nsc he d ule d V isit, he/s he m ust be a d vise d t o ret ur n t o t he of fice weari n g t he 
st u d y  le nses, if at all p ossi ble ( u nless he/s he is e x perie nci n g a si g n or s y m pt o m [as i n dicate d 
i n Secti o n 3. 3 Ris ks a n d Be nefits]). D uri n g all u nsc he d ule d visits, t he I n vesti gat or m ust 
c o n d uct t he f oll o wi n g pr oce d ures: 
C ollect A E a n d de vice deficie nc y  i nf or mati o n 
Assess a n d rec or d c ha n ges i n m e dical c o n diti o n or c o nc o mita nt me dicati o n 
Assess a n d rec or d V As 
Perf or m bi o micr osc o p y (assess me nts wit h or wit h o ut le nses, as p ossi ble) 
I n a d diti o n, all pr oce d ures f or V isit 3( F oll o w -u p Le ns 2 / E xit) s h o ul d be c o m plete d (as 
p ossi ble). T he I n vesti gat or ma y perf or m a d diti o nal pr oce d ures f or pr o per dia g n osis a n d 
treat me nt of t he s u bject. T he I n vesti gat or m ust d oc u me nt t his i nf or mati o n i n t he s u bject’ s 
case hist or y  s o urce d oc u me nts. 
If d uri n g a n U nsc he d ule d V isit t he s u bject is disc o nti n ui n g t he st u d y  le nses or disc o nti n ui n g 
fr o m t he st u d y , t he I n vesti gat or m ust c o n d uct E xit pr oce d ures acc or di n g t o Ta ble 1 -1: 
Sc he d ule of St u d y  Pr oce d ures a n d Assess me nts , as p ossi ble. 
5. 3 Disc o nti n ue d S u bjects Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767201] d (ie, t heir s u bject n u m bers will n ot be 
re -assi g ne d/re -use d). 
S h o ul d a s u bject e x hi bit a n y  cli nicall y  rele va nt si g ns, s y m pt o ms, or ot her cli nical 
o bser vati o ns t hat p ossi bl y  c o ul d be ass ociate d wit h s us pec te d se nsiti vit y  or i nt olera nce t o o ne 
of t he st u d y  treat me nts, t he I n vesti gat or m ust d oc u me nt t h ose o bser vati o ns o n a n A E F or m. 
A n y  s u bject w h o e xits earl y  fr o m t he st u d y  (e xcl u di n g scree n fail ures) m ust u n der g o all 
pr oce d ures o utli ne d at Visit 3, as a p plica ble .
Pa ge [ADDRESS_767202]’ s case hist or y  s o urce d oc u me nts. 
To e ns ure t he safet y of all s u bjects w h o disc o nti n ue earl y,  I n vesti gat ors m ust assess eac h 
s u bject a n d, if necessar y,  a d vise t he m of a n y t hera pi[INVESTIGATOR_014] a n d/ or me dical pr oce d ures t hat m a y be 
nee de d t o mai ntai n t heir healt h. 
5. [ADDRESS_767203] u d y  S p o ns or: 
T he St u d y  S p o ns or m ust :
oIm me diatel y  n otif y  t he I n vesti gat or (s) a n d s u bse q ue ntl y  pr o vi de i nstr ucti o ns f or 
st u d y  ter mi nati o n. 
oInf or m t he I n vesti gat or a n d t he re g ulat or y  a ut h orities of t he 
ter mi nati o n/s us pe nsi o n a n d t he reas o n(s) f or t he ter mi nati o n/s us pe nsi o n , as 
a p plica ble. 
T he I n vesti gat or m ust: 
oPr o m ptl y  n otif y  t he I R Bof t he ter mi nati o n or s us pe nsi o n a n d of t he reas o ns. 
oPr o vi de s u bjects wit h rec o m me n dati o ns f or p ost -st u d y  treat me nt o pti o ns as 
nee de d. 
T he I n vesti gat or ma y  ter mi nate a site’ s partici pati o n i n t he st u d y  f or reas o na ble ca use. 
6A N A L Y SI S P L A N Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767204] evaluability  will be determined prior to breaking the code for masked 
treatment sequence assignment and locking the database, based on the Deviations and 
Evaluability  Plan.
6.2 Analysis Data Sets
6.2.1 Safety Analysis Set
Safety  anal yses will be conducted using the safet y anal ysis set on a treatment- emergent basis. 
As such, t he safety  anal ysis set will include all subjects/eyes exposed to any study  lenses
evaluated in this study . For treatment -emer gent safety  anal yses, subjects/eyes will be 
categorized under the actual study  lenses exposed . 
6.3 Demographic and Baseline Characteristics
Demographic information (age, sex, ethnicity , race) will be summarized on the Safety 
Analy sis Set Baseline data pertaining to habitual lens  
 will be summarized on the Safet y Anal ysis Set as well.
6.[ADDRESS_767205] .The primary  endpoint is 
the subjective rating on overall quality
 of vision, collected binocularl y on a scale of 1 (Poor) 
to 10 (Excellent).
[IP_ADDRESS] Statistical Hypotheses
No inferences are to be made on the primary  effectiveness endpoint/s, therefore no 
hypotheses are formulated.
[IP_ADDRESS] Analysis Methods
Descriptive statistics will be provided. 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054506
Protocol - Clinical
02-Nov-2017

Page 24of 38
6.4.2 Secondary Effectiveness
No secondary  objective or endpoint is defined for this study .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767206] on the 
study  results in this study . No subgroup anal yses are planned.
6.6 Handling of Missing Data
All data obtained in evaluable subjects/ey es will be included in the analy sis. No imputation 
for missing values will be carried out for the primary  anal ysis.
6.7 Multiplicity
No multiplicity  adjustment needs to be considered for the effectiveness endpoints since no 
formal h ypothesis testing will be conducted.
6.8 Safety Analysis
The safet y endpoints for this study  are AEs, biomicroscop y findings, and device deficiencies. 
Data for DD T2 will be summarized according to the crossover control worn per each parallel 
group.
Descriptive summaries (counts and percentages) for ocular and nonocular AEs will be 
presented b y Medical Dictionary  for Regulatory  Activities Preferred T erms. AEs leading to 
study  discontinuation, significant non- serious AEs, and SAEs will be identified. I ndividual 
subject listings will be provided, as necessary . 
Individual subject listings will be provided for AEs that occur after signing informed consent 
but prior to exposure to study  lenses . 
Each biomicroscop y parameter will be tabulated by [CONTACT_13296]. For each biomicroscop y 
parameter , counts and percentages of ey es that experience an increase of 
≥ 2 grades from 
Baseline (V isit 1) to any  subsequent visit will be presented. A supportive listing will be 
generated which will include all biomicroscop y data f rom all visits for these ey es 
experiencing the increase.
Two listings (prior to exposure of stud y lenses and treatment -emergent) of device 
deficiencies, as recorded on the Device Deficiency Form, will be provided. Additionally , each 
device deficiency  categ ory will be tabulated. 
No inferential testing will be done for safet y anal ysis. 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767207] an interim anal ysis and no criteria b y which the study would be 
terminated early  based upon statistical determination. 
7ADVERSE EVENTS AND DEVICE DEFICIENCIES
Table7-1 Terms and Definitions
Adverse event (AE) Any untoward medical occurrence, unintended disease or injury , or 
untoward clinical signs (including abnormal laboratory  findings) in 
subjects, users or other persons, whether or not related to the 
investigational medical device (test product). 
Note: For 
subjects, this definition includes events r elated to the 
test pr oduct, the contr ol pr oduct, or the pr ocedur es involved. For 
users or other persons, this definition is r estricted to events r elated 
to the test pr oduct.
Adverse device effect 
(ADE)AE related to the use of an investigational medical device (test 
product ) or control pr oduct. 
Note: This definition includes AEs r esulting fr om insufficient or 
inadequate instructions for use, deployment, implantation, 
installation, or operation; any malf unction; and use err or or 
intentional misuse of the test pr oduct or contr ol pr oduct.
Anticipated serious 
adverse device effect 
(ASADE)Serious ADE which b y its nature, incidence, severity  or outcome 
has been identified in the risk management file.
Device deficiency Inadequacy  of a medical device with respect to its identity , quality , 
durability , reliability , safety , or performance. 
Note: This definition includes malfunctions, use err ors, and 
inadequate labeling.
Malfunction Failure of a medical de vice to meet its performance specifications 
or otherwise perform as intended. Performance specifications 
include all claims made in the labeling of the device. The intended 
performance of the device refers to the intended use for which the 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054506
Protocol - Clinical
02-Nov-2017

Pa ge 2 7 of 3 8 
de vice is la bele d or mar kete d. 
N o n -seri o us ad verse 
eve nt A E t hat d oes n ot meet t he criteria f or a n S A E. 
Seri o us ad verse eve nt 
( S A E) A E t hat le d t o a n y of t he f oll o wi n g: 
Deat h. 
A seri o us deteri orati o n i n t he healt h of t he s u bject t hat eit her 
res ulte d i n: 
a) a life -t hreate ni n g ill ness or i nj ur y .
N ote: Life -t hr e ate ni n g me a ns t h at t he i n divi d u al w as at 
i m me di ate risk of de at h fr o m t he eve nt as it occ urr e d, ie, it 
d oes n ot i ncl u de a n eve nt w hic h hy p ot hetic ally mi g ht h ave 
c a use d de at h h a d it occ urr e d i n a m or e sever e f or m. 
b) a n y  p ote ntiall y  si g ht -t hreate ni n g e ve nt or per ma ne nt 
i m pair me nt t o a b o d y  str uct ure or a b o d y  f u ncti o n. 
c) i n -patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n ge d h os pi[INVESTIGATOR_1314] o n. 
N ote: Pl a n ne d h os pit aliz ati o n f or a pr e- existi n g c o n diti o n, 
wit h o ut seri o us deteri or ati o n i n he alt h, is n ot c o nsi der e d 
a n S A E. I n ge ner al, h os pit aliz ati o n si g nifies t h at t he 
i n divi d u al r e m ai ne d at t he h os pit al or e mer ge ncy w ar d f or 
o bserv ati o n a n d/ or tr e at me nt ( us u ally i nv olvi n g a n 
over ni g ht st ay) t h at w o ul d n ot h ave bee n a p pr o pri ate i n t he 
p hysici a n's office or a n o ut - p atie nt setti n g. C o m plic ati o ns 
t h at occ ur d uri n g h os pit aliz ati o n ar e a dverse eve nts. If a 
c o m plic ati o n pr ol o n gs h os pit aliz ati o n or f ulfills a ny ot her 
seri o us criteri a, t he eve nt is seri o us. W he n i n d o u bt as t o 
w het her “ h os pit al iz ati o n ” occ urr e d, t he eve nt s h o ul d be 
c o nsi der e d seri o us. 
d) a me dical or s ur gical i nter ve nti o n t o pre ve nt a) or b). 
e) a n y  i n direct har m as a c o nse q ue nce of i nc orrect dia g n ostic 
test res ults w he n use d wit hi n ma n ufact urer ’s  i nstr ucti o ns 
f or use. 
Fetal distress , fetal deat h, or a c o n ge nital a b n or malit y  or birt h 
defect. 
Refer t o Secti o n 7. [ADDRESS_767208] ( S A D E) A D E t hat has res ulte d i n a n y  of t he c o nse q ue nces c haracteristic of 
a n S A E. 
Si g nifica nt n o n- A si g nifica nt n o n -seri o us A E is a s y m pt o matic, de vice -relate d, Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767209] 
([LOCATION_003]DE)Serious adverse device effect which b y its nature, incidence, 
severit y or outcome has not been identified in the risk management 
file.
Use Error Act or omission of an act that results in a dif ferent medical device 
response than intended by [CONTACT_13298]. 
Note: This definition includes slips, lapses, and mistakes. An 
unexpected physiological r esponse of the subject does not in it self 
constitute a use err or.
7.[ADDRESS_767210] 
clinical signs (including abnormal laboratory  findings) in subjects, users, or other persons, 
whether or not related to t he investigational medical device (test article ).
Figur e 7–1 Categorization of All AEs
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054506
Protocol - Clinical
02-Nov-2017
Pa ge 2 9 of 3 8 
Fi g ur e 7- 2 C ate g oriz ati o n of All Seri o us A d verse E ve nts 
Seri o us A dverse Eve nts 
I n a d diti o n t o re p orti n g all A Es (seri o us a n d n o n -seri o us) meeti n g t he defi niti o ns, t he 
I n vesti gat or m ust re p ort a n y  occ urre nce of t he f oll o wi n g as a n S A E: 
A n oc ular i nfecti o n i ncl u di n g a p res u me d i nfecti o us ulcer wit h a n y of t he f oll o wi n g 
c haracteristics: 
oCe ntral or parace ntral l ocati o n 
oPe netrati o n of B o w ma n’ s me m bra ne 
oI n filtrates > 2 m m dia meter 
oIritis 
oI n crease i n i ntra oc ular press ure 
oC ult ure p ositi ve f or micr o or ga nis ms 
oI n creasi n g size or se verit y  at s u bse q ue nt visits 
A n y  ce ntral or parace ntral c or neal e ve nt (s uc h as ne o vasc ularizati o n) t hat res ults i n 
per ma ne nt o pacificati o n 
H y p o p y o n 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 5 0 6 P r o t o c o l  -  C l i n i c a l 0 2- N o v- 2 0 1 7 
H y p he ma 
Pa ge 3 0 of 3 8 
Ne o vasc ularizati o n wit hi n t he ce ntral 6 m m of t he c or nea 
Per ma ne nt visi o n l oss as defi ne d b y l oss of 2 or m ore li nes of B C V A fr o m e nr oll me nt 
visit t hat fails t o res ol ve 
U veitis (a nteri or , i nter me diate, or p osteri or) 
C or neal a brasi o n affecti n g ≥ 5 0 % of c or neal s urface area 
Si g nific a nt N o n -Seri o us A dverse Eve nts 
A si g nifica nt n o n -seri o us A E is a s y m pt o ma tic, de vice -relate d, n o n -si g ht t hreate ni n g A E t hat 
warra nts disc o nti n uati o n of a n y c o ntact le ns wear f or greater t ha n or e q ual t o [ADDRESS_767211] re p ort a n y  occ urre nce of t he f oll o wi n g as a Si g nifica nt 
N o n - Seri o us A E: 
Peri p heral n o n- pr o gressi ve n o n- i nfecti o us ulcers 
All s y m pt o matic c or neal i nfiltrati ve e ve nts 
C or neal stai ni n g sc ore greater t ha n or e q ual t o Gra de 3 ( Refer t o M O P f or gra di n g 
scales) [ Gra di n g scale is base d o n I S O 1 1 9 8 0: 2 0 1 2 u nless s pecifie d differe ntl y  i n 
M O P] 
Te m p orar y  visi o n l oss as defi ne d b y  l oss of 2 or m ore li nes of B C V A fr o m e nr oll me nt 
visit t hat persists f or 2 or m ore wee ks 
Ne o vasc ularizati o n sc ore greater t ha n or e q ual t o Gra de 2 
T he a b ove eve nts ar e b ase d u p o n t he c ate g ories pr ovi de d i n t he I S O 1 1 9 8 0 : 2 0 1 2 a n d t he U S 
F D A Pr e m arket N otific ati o n ( 5 1 0(k)) G ui d a nce D oc u me nt f or D aily W e ar C o nt act Le nses 
a n d C o nt act Le ns C ar e Pr o d ucts. 
Device Deficie ncies 
A de vice deficie nc y  is i na de q uac y  of a me dical de vice wit h res pect t o its i de ntit y , q ualit y , 
d ura bilit y , re lia bilit y , safet y , or perf or ma nce. A de vice deficie nc y  ma y  or ma y  n ot be 
ass ociate d wit h patie nt har m (ie, A D E or S A D E); h o we ver , n ot all A D Es or S A D Es are d ue 
t o a de vice deficie nc y . T he I n vesti gat or s h o ul d deter mi ne t he a p plica ble cate g or y liste d i n t he 
De vice Deficie nc y  e C R F f or t he i de ntifie d or s us pect de vice deficie nc y  a n d re p ort a n y patie nt 
har m se paratel y . E xa m ples of de vice deficie ncies i ncl u de t he f oll o wi n g: 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767212] s pecificati o ns (e g, i nc orrect le ns p o wer/ dia meter/ base 
c ur ve/c ol o r) 
Pa ge 3 1 of 3 8 
Le ns cl o u d y
Le ns s urface/e d ge defect 
To r n le ns d uri n g ha n dli n g/i n pac k 
Pac ka gi n g deficit (e g, misla bele d pr o d uct, ta m pere d seal, lea ki n g b ottle/c o ntai ner) 
S us pect pr o d uct c o nta mi nati o n 
Lac k of perf or ma nce 
7. [ADDRESS_767213] has ha d t he o p p ort u nit y  t o s p o nta ne o usl y me nti o n a n y 
pr o ble ms, t he I n vesti gat or s h o ul d i n q uire a b o ut A Es b y  as ki n g t he sta n dar d q uesti o ns: 
“ Ha ve y o u ha d a n y healt h pr o ble ms si nce y o ur last st u d y  visit?” 
“ Ha ve t here bee n a n y c ha n ges i n t he me dici nes y o u ta ke si nce y o ur last st u d y  visit?” 
A d diti o nall y , c ha n ges i n a ny pr ot oc ol -s pecific p ar a meters a n d/ or q uesti o n n air es e val uate d 
d uri n g t he st u d y are t o be re vie we d b y t he I n vesti gat or . A n y u nt o war d ( u nfa v ora ble a n d 
u ni nte n de d) c ha n ge i n a pr ot o c ol -s pecific p ar a meter or q uesti o n n air e r es p o nse t hat is 
cli nicall y  rele va nt, i n t he o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or , is t o be re p orte d as a n A E. T hese 
cli nicall y  rele va nt c ha n ges will be re p orte d re gar dless of ca usalit y . 
7. 3 Pr oce d ures f or Rec or di n g a n d Re p orti n g
A Es are c ollecte d fr o m t he ti me of i nf or me d c o nse nt. A n y pre -e xisti n g me dical c o n diti o ns or 
si g ns/s y m pt o ms prese nt i n a s u bject pri or t o t he start of t he st u d y  (ie, bef ore i nf or me d 
c o nse nt is si g ne d) are n ot c o nsi dere d A Es i n t he st u d y  a n d s h o ul d be rec o r de d i n t he Me dical 
Hist or y  secti o n of t he e C R F .
I n a d diti o n, te m p orar y  le ns a ware ness or vis ual c ha n ges d uri n g t he fitti n g pr ocess are n ot 
c o nsi dere d A Es if t he I n vesti gat or assesses t hat t he s y m pt o m(s) ca n reas o na bl y  res ol ve wit hi n 
t he a ntici pate d a da pta ti o n peri o d. 
A D Es or S A Es are d oc u me nte d o n t he Seri o us A dverse Eve nt a n d A dverse Device 
Effect e C R F wit hi n 2 4 h o urs of t he I n vesti gat or ’s  or site’ s a ware ness . 
De vice deficie ncies are d oc u me nte d o n t he Device Deficie ncy Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767214] i g at or ’s  or site’ s a ware ness . 
Pa ge 3 2 of 3 8 
A pri nte d c o p y of t he c o m plete d Seri o us A dverse Eve nt a n d A dverse Device Effect 
a n d/ or Device Deficie ncy e C R F m ust be i ncl u de d wit h pr o d uct ret ur ns. 
A d diti o nal rele va nt i nf or mati o n after i nitial re p orti n g m ust be e ntere d i nt o t he e C R F as 
s o o n as t he data bec o me a vaila ble. 
D oc u me nt a n y c ha n ges t o c o nc o mita nt me dicati o ns o n t he a p pr o priate e C R Fs. 
D oc u me nt all rele va nt i nf or mati o n fr o m Disc har ge S u m mar y , A ut o ps y  Re p ort, 
Certificate of Deat h, etc, if a p plica ble, i n narrati ve sect i o n of t he Seri o us A dverse 
Eve nt a n d A dverse Device Effect e C R F .
N ote: S h o ul d t he E D C s yste m bec o me n o n -o perati o nal, t he site m ust c o m plete t he 
a p pr o priate pa per Seri o us A dverse Eve nt a n d A dverse Device Effect a n d/ or Device Deficie ncy 
F or m. T he c o m plete d f or m is e maile d t o t he St u d y  S p o ns or at  
acc or di n g t o t he ti meli nes o utli ne d a b o ve; h o we ver , t he re p orte d i nf or mati o n m ust be e ntere d 
i nt o t he E D C s y ste m o nce it bec o mes o perati o nal. 
A n y  A Es a n d de vice deficie ncies f or n o n -st u d y  mar kete d de vices/ pr o d ucts will be c o nsi dere d 
a n d pr ocesse d as s p o nta ne o us (f oll o wi n g t he p ost mar ket vi gila nce pr oce d ures) a n d s h o ul d be 
c o m m u nicate d t o t he de vice’s/ pr o d uct’s ma n ufact urer as per l ocal re q uire me nts. 
St u d y  S p o ns or re prese ntati ves ma y  be c o ntacte d f or a n y  pr ot oc ol relate d q uesti o n a n d t heir 
c o ntact i nf or mati o n is pr o vi de d i n t he M O P t hat acc o m pa nies t his pr ot oc ol .
F urt her , de pe n di n g u p o n t he nat ure of t he A E or de vice deficie nc y  bei n g re p orte d, t he St u d y  
S p o ns or ma y  re q uest c o pi [INVESTIGATOR_1309] a p plica ble p orti o ns of t he s u bject’ s me dical rec or ds. T he 
I n vesti gat or m ust als o re p ort all A Es a n d de vice deficie ncies t hat c o ul d ha ve le d t o a S A D E 
acc or di n g t o t he re q uire me nts of re g ulat or y  a ut h orities or I R B/I E C. 
I nte nsit y a n d C a us alit y Assess me nts 
W here a p pr o priate, t he I n vesti gat or m ust assess t he i nte nsit y  (se verit y) of t he A E base d u p o n 
me dical j u d g me nt wit h c o nsi derati o n of a n y s u bjecti ve s y m pt o m(s), as defi ne d bel o w: 
I nte nsity ( Severity) Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767215]’ s us ual acti vities. 
Page 33of [ADDRESS_767216]’ s inability  to work or engage in their usual activities.
For every  AE in the study , the Investigator must assess the causalit y (Related or Not Related 
to the medical device or study  procedure). An assessment of causality  will also be performed 
by [CONTACT_13302], as shown below:
Causality
Related An AE classified as related may  be either definitely  related or possibl y related 
where a direct cause and ef fect relationship with the medical device or study  
procedure has not been demonstrated, but there is a reasonable possibility  that 
the AE was caused by  [CONTACT_13303] y procedure.
Not Related An AE classified as not related may  either be definitely  unrelated or simply  
unlikely  to be related (ie, th ere are other more likely  causes for the AE).
The Study  Sponsor will assess the AEs and may  upgrade the Investigator ’s assessment of 
seriousness and/or causality . The Study  Sponsor will notify  the Investigator of an y AEs that 
are upgraded from non -serious to serious or from unrelated to related.
7.[ADDRESS_767217] analysis
Alcon products associated with device deficiencies and/or product related AEs should be 
returned and must include the Complaint # which will be provided by  [CONTACT_583630] ’s Global Product Complaint Management Sy stem. These 
products should be returned to the Sponsor at the end of the study , unless instructed otherwise 
by [CONTACT_1034] . 
7.5 Follow -Up of Subjects with Adverse Events
The Investigator i s responsible for adequate and safe medical care of subjects during the 
study  and for ensuring that appropriate medical care and relevant follow -up procedures are 
maintained after the study . 
The Investigator should provide the Study  Sponsor with any  new s afety information (which 
includes new AEs and changes to previousl y reported AEs) that may  affect the safet y 
evaluation of the device. For AEs that are unresolved/ ongoing at time of subject exit from 
study , any  additional information received at follow -upshould be documented in the eCRFs 
up to study  completion (ie, database lock).
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767218] be 
documented and available upon the Study  Sponsor ’s request. All complaints received after
this time period will be considered and processed as spontaneous and should be 
communicated to the medical device’ s manufacturer as per local requirements.
The Investigator should also report complain ts on non- Alcon products directly  to the 
manufacturer a s per the manufacturer ’s instructions or local regulatory  requirements.
7.6 Pregnancy in the Clinical Study
Women of childbearing potential or women who are pregnant at the time of study  entry  are 
not excluded from participation. Pregnancy  should be includ ed in the Medical History  section 
of the eCRF when a pregnant woman enters the study  or if a woman becomes pregnant 
during the stud y. Pregnancy  is not reportable as an AE; however , complications may  be 
reportable and will be decided on a case –by-case basis .
8CONFIDENTIALITY , BIAS, AND MASKING
8.[ADDRESS_767219]’ s anony mity is maintained throughout the 
course of the stud y. In particular
, the Investigator must keep an enrollment log with 
confidential identify ing information that corresponds to the subject numbers and initials of 
each stud y participant. At the end of the clinical study , the Sponsor will collect a cop y of the 
enrollment log without any  identify ing subject information. All documents submitted to the 
Sponsor will identify  the subjects exclusively  by [CONTACT_13305]. No 
other personall y identifying information should be transmitted to the Sponsor .
This study  is double -masked with subjects randomized to use both DD T2 and the assigned 
control product (in a randomized sequence) for the duration of the treatment period. The 
Investigator and Sponsor personnel (other than site monitors, lead clinical site manager , 
person responsibl e for generating the randomization schedule, and unmasked clinical data 
managers) involved in reporting, obtaining, and/or reviewing the clinical evaluations will be 
masked to the identity  of the contact [CONTACT_13306]. This level of masking will be 
maintained throughout the conduct of the stud y. Unmasking will occur only after all planned 
study  data have been validated, and the database locked. Masked stud y personnel must avoid 
seeking information that may  compromise masking. Unmasked study  person nel must not 
disseminate information that is potentially  unmasking to any  masked personnel. The masked 
and unmasked site personnel must coordinate all study  activities as necessary  to protect 
masking and minimize bias during the trial.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767220] u d y  S p o ns or re prese ntati ve pri or t o 
u n mas ki n g t he i nf or mati o n if t here is s ufficie nt ti me. De pe n de nt u p o n t he i n di vi d ual 
circ u msta nces (ie, me dical e mer ge nc y ), t he c o de ma y  be br o ke n pri or t o c o ntact wit h t he 
St u d y  S p o ns or. T he St u d y  S p o ns or m ust be i nf or m e d of all cases i n w hic h t he c o de was 
br o ke n a n d of t he circ u msta nces i n v ol ve d. A d diti o nall y , t he St u d y  S p o ns or ma y  be re q uire d 
t o u n mas k t he i nf or mati o n i n or der t o f ulfill e x pe dite d re g ulat or y  re p orti n g re q uire me nts. 
9D A T A  H A N D LI N G A N D A D MI NI S T R A TI V E R E Q U I R E M E N T S 
9. [ADDRESS_767221]: 
S u bject i de ntificati o n ( na me, se x, race/et h nicit y) 
D oc u me ntati o n of s u bject eli gi bilit y 
Date of i nf or me d c o nse nt 
Dates of visi ts 
D oc u me ntati o n t hat pr ot oc ol s pecific pr oce d ures were perf or me d 
Res ults of st u d y  para meters, as re q uire d b y t he pr ot oc ol 
I P  acc o u nta bilit y  rec or ds 
D oc u me ntati o n of A Es a n d ot her safet y para meters (if a p plica ble) 
Rec or ds re gar di n g me dical hist ories a n d t h e use of c o nc o mita nt t hera pi[INVESTIGATOR_258755] t o a n d 
d uri n g t he st u d y
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_767222] access 
to source documentat ion (medical records) must be allowed for the purpose of verify ing that 
the data recorded on the eCRF are consistent with the original source data.
Only  designated individuals may  complete the eCRFs. The eCRFs will be submitted at 
regular intervals followi ng the clinical study  visit schedule. It is expected that all data 
reported will have corresponding entries in the source documents. The Principal Investigator 
[INVESTIGATOR_583623]. The 
only subject identifiers recorded on the eCRFs will be subject number , and subject 
demographic information.
9.[ADDRESS_767223]’ s source 
data will be completed by [CONTACT_512903] . Additional 
data clarifications and/or additions may  be needed as a result of the data cleaning process. 
Data clarifications are documented and are part of each subject’ s eCRFs.
9.3 Regulatory Documentation and Reco rds Retention
The Investigator is required to maintain up- to-date, complete regulatory  documentation as 
indicated by [CONTACT_66229] ’s files will be reviewed as part of the ongoing 
study  monitoring. Financial disclosure is not subject to r egulatory  inspection and should be 
kept separately . 
Additionally , the Investigator must keep study records and source documents until the 
Sponsor provides written approval for their destruction. If the Investigator retires, relocates, 
or for an y other rea son withdraws from responsibility  of keepi[INVESTIGATOR_13274], the 
Sponsor must be notified and suitable arrangements made for retention of study  records and 
source documents needed to comply  with national and international regulations (generall y 
2years after discontinuing clinical development or after the last marketing approval).
10ETHICS AND COMPLIANCE
This trial will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki and the referenced directives, regulations, guidelines, and/or 
standards.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767224] the clinical study  in 
compliance with the protocol. Deviations from this protocol, regulatory  requirements and/or 
GCP  must be recorded and reported to the Sponsor prior to database lock. If needed, 
corrective and preventive action should be identified, implemented, and documented within 
the study  records.
10.[ADDRESS_767225] (IRB)
This trial requires IRB approval prior to initiation. This protocol, subject informed consent, 
and subsequent amendme nts will be reviewed and approved b y an IRB.
Before clinical study  initiation, this protocol, the ICF (and assent form, if applicable), an y 
other written information given to subjects, and any  advertisements planned for subject 
recruitment must be approved by [CONTACT_2717]. The Investigator must provide documentation of 
the IRB approval to the Study  Sponsor . The approval must be dated and must identify  the 
applicable protocol, amendments (if an y), ICF , assent form (if an y), all applicable recruiting 
materials, wri tten information for subject, and subject compensation programs. The I RB must 
be provided with a cop y of the Investigator ’s Brochure , any periodic safet y updates, and all 
other information as required by  [CONTACT_13308]/or the I RB. At the end of the study , the 
Investigator must notify  the I RB about the study ’s completion. The IRB also must be notified 
if the study  is terminated prematurel y. Finall y, the Investigator must report to the I RB on the 
progress of the stud y at intervals stipulated by [CONTACT_941] I RB.
Voluntary  informed consent must be obtained from every  subject (and/or legal representative, 
as applicable) prior to the initiation of any  screening or other study -related procedures. The 
Investigator must have a defined process for obtaining consent. Spe cifically , the Investigator , 
or delegate, must explain the clinical study  to each potential subject and the subject must 
indicate voluntary  consent by  [CONTACT_13309]. The 
subject must be provided an opportunity  to ask questions of the Investigator , and if required 
by [CONTACT_1295], other qualified personnel. The Investigator must provide the subject with 
a cop y of the consent form written in a language the subject understands. The consent 
document must meet all appl icable local laws and provide subjects with information 
regarding the purpose, procedures, requirements, and restrictions of the study , along with any  
known risks and potential benefits associated with the I P, the available compensation, and the 
establishe d provisions for maintaining confidentiality  of personal, protected health 
information. Subjects will be told about the voluntary  nature of participation in the study  and 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_767226] le nses. 
1 1 P R O T O C O L  A M E N D M E N T HI S T O R Y
Versi o n Brief Descri pti o n a n d R ati o n ale 
1 I nitial V ersi o n of t his d oc u me nt 
1 2 R E F E R E N C E S 
1 2. 1 Refere nces a p plic a ble f or all cli nic al tri als 
I S O 1 1 9 8 0: [ADDRESS_767227] le ns care pr o d ucts -
G ui da nce f or cli nical i n vesti gati o ns 
I S O 1 4 1 5 5: 2 0 1 1 Cli nical i n vesti gati o n of me dical de vices f or h u ma n s u bjects - G o o d 
cli nical practice 
1 2. 1. 1 U S refere nces a p plic a ble f or cli nic al tri als 
2 1 C F R Part 1 1 - Electr o nic Rec or ds; Electr o nic Si g nat ures 
2 1 C F R Part 5 0 -Pr otecti o n of H u ma n S u bjects 
2 1 C F R Part 5 6 - I nstit uti o nal Re vie w B oar ds 
2 1 C F R Part 8 1 2 - I n vesti gati o nal De vice E xe m pti o ns 
2 1 C F R Part 5 4 - Fi na ncial Discl os ure b y Cli nical I n vesti gat ors 
T he Calif or nia Bill of Ri g hts .
1 2. 2 Refere nces f or t his cli nic al tri al Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 5 0 6 P r o t o c o l  -  C l i n i c a l 0 2- N o v- 2 0 1 7 
N ot a p plica ble. 
                                                                                                                
                                                                                     
Date/Time 
(mm/dd/yyyy GMT): Signed by: [CONTACT_13310] :
11/02/2017 13:25:44
10/31/2017 20:07:40
10/31/2017 19:36:06
10/31/2017 19:36:06
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054506
Protocol - Clinical
02-Nov-2017
